CTLT

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”

Lisata Therapeutics CEO discusses Catalent deal - ICYMI

Lisata Therapeutics inks global product license deal with Catalent

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research